Vermillion (VRML) Set to Announce Quarterly Earnings on Tuesday

Vermillion (NASDAQ:VRML) is scheduled to announce its earnings results after the market closes on Tuesday, May 14th.

Vermillion (NASDAQ:VRML) last issued its quarterly earnings data on Thursday, March 28th. The company reported ($0.04) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.04). The firm had revenue of $0.92 million for the quarter. Vermillion had a negative net margin of 372.45% and a negative return on equity of 150.85%.

Shares of NASDAQ:VRML opened at $1.33 on Monday. Vermillion has a fifty-two week low of $0.27 and a fifty-two week high of $1.57. The company has a current ratio of 3.64, a quick ratio of 3.61 and a debt-to-equity ratio of 0.18.

Separately, ValuEngine downgraded shares of Vermillion from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st.

In related news, Director David Schreiber sold 30,000 shares of Vermillion stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $1.00, for a total value of $30,000.00. Following the sale, the director now directly owns 137,405 shares in the company, valued at approximately $137,405. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 4.25% of the company’s stock.

WARNING: This report was first posted by Markets Daily and is the property of of Markets Daily. If you are reading this report on another website, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this report can be viewed at https://www.themarketsdaily.com/2019/05/13/vermillion-vrml-set-to-announce-quarterly-earnings-on-tuesday.html.

About Vermillion

Vermillion, Inc, together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women primarily in the United States. The company's diagnostic tests include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor; and Overa, a multivariate index assay second generation test to determine the malignancy of ovarian cancer in women.

Recommended Story: How is net asset value different from market price?

Earnings History for Vermillion (NASDAQ:VRML)

Receive News & Ratings for Vermillion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vermillion and related companies with MarketBeat.com's FREE daily email newsletter.